AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11290479 — intervention group
Group type: EXPERIMENTAL
Intervention: IV rt-PA
Number of subjects: 35
Study 11290479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 9335514 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study 9335514 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 0
Study 9335514 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxoid therapy (combination with various chemotherapeutic agents and monoclonal antibodies)
Number of subjects: 0
Study 9335514 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxoid monotherapy or combination therapy
Number of subjects: 0
Study 9335514 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxoids
Number of subjects: 0
Study 9335514 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxoids in randomized adjuvant trials
Number of subjects: 0
Study 8201963 — intervention group
Group type: EXPERIMENTAL
Intervention: L-phenylalanine (10 g)
Number of subjects: 6
Study 8201963 — intervention group
Group type: COMPARATOR
Intervention: D-phenylalanine (D-PA)
Number of subjects: 6
Study 8201963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2906873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 24
Study 2906873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramixotidine 750 mg (CM 57755A)
Number of subjects: 24
Study 2906873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31095060 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent health information technology mental health screening intervention
Number of subjects: 390
Study 31095060 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline care
Number of subjects: 390
Study 31095060 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-informed care
Number of subjects: 390
Study 31095060 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control group
Number of subjects: 390
Study 28502786 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Graded Exercise Therapy (GET) for 12 weeks
Number of subjects: 46
Study 28502786 — intervention group
Group type: COMPARATOR
Intervention: Education (single visit with clinicians and a booklet)
Number of subjects: 46
Study 25506778 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat meal (930kcal, 60g fat)
Number of subjects: 43
Study 25506778 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleic sunflower oil meal (930kcal, 60g fat)
Number of subjects: 43
Study 25506778 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with a mood disorder history
Number of subjects: 43
Study 25506778 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of hostile behaviors
Number of subjects: 43
Study 25506778 — intervention group
Group type: COMPARATOR
Intervention: Comparison of the two meals
Number of subjects: 43
Study 22948337 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Matters intervention along with usual care
Number of subjects: 178
Study 22948337 — intervention group
Group type: COMPARATOR
Intervention: Usual Care alone
Number of subjects: 178
Study 21761129 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC/SRL group (n = 24)
Number of subjects: 47
Study 21761129 — intervention group
Group type: COMPARATOR
Intervention: SRL/ST group (n = 21)
Number of subjects: 47
Study 18320559 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 6 weeks
Number of subjects: 88
Study 18320559 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD‐3 polymorphisms in disequilibrium with ser‐9‐gly
Number of subjects: 88
Study 18320559 — intervention group
Group type: EXPERIMENTAL
Intervention: One DRD‐3 polymorphism not in complete linkage disequilibrium
Number of subjects: 88
Study 16438763 — intervention group
Group type: COMPARATOR
Intervention: Diprivan
Number of subjects: 60
Study 16438763 — intervention group
Group type: COMPARATOR
Intervention: Generic propofol
Number of subjects: 60
Study 12904191 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L10F25 (10 mg lidocaine plus 25 microg fentanyl)
Number of subjects: 75
Study 12904191 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L10F25E15 (10 mg lidocaine plus 25 microg fentanyl plus 15 microg epinephrine)
Number of subjects: 75
Study 12904191 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L20F25 (20 mg lidocaine plus 25 microg fentanyl)
Number of subjects: 75
Study 10946428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized trials
Number of subjects: 0
Study 9049593 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia serrata gum resin (350 mg thrice daily for 6 weeks)
Number of subjects: 0
Study 9049593 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (1 g thrice daily)
Number of subjects: 0
Study 8349341 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin traction
Number of subjects: 100
Study 8349341 — intervention group
Group type: COMPARATOR
Intervention: No traction
Number of subjects: 100
Study 3519694 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocarboxazid (50 mg)
Number of subjects: 0
Study 3519694 — intervention group
Group type: COMPARATOR
Intervention: Isocarboxazid
Number of subjects: 0
Study 30557404 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1,000 IU/day) and Calcium (1,200 mg/day)
Number of subjects: 104
Study 30557404 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 alone
Number of subjects: 104
Study 30557404 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alone
Number of subjects: 104
Study 30557404 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 104
Study 28475205 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic ELF‐MF therapy (100 microtesla, 1 to 80 Hz)
Number of subjects: 37
Study 28475205 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 37
Study 28475205 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF‐MF therapy
Number of subjects: 37
Study 23812596 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Zol) 5 mg intravenous once yearly
Number of subjects: 2127
Study 23812596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study 22490477 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 100 mg intravenously 15 minutes before incision (PA group)
Number of subjects: 60
Study 22490477 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (C group)
Number of subjects: 60
Study 22490477 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (PA group)
Number of subjects: 60
Study 21284135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion monotherapy (switching strategy)
Number of subjects: 2
Study 21284135 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release bupropion plus citalopram (combination strategy)
Number of subjects: 2
Study 21284135 — intervention group
Group type: COMPARATOR
Intervention: Combination regimen
Number of subjects: 2
Study 21284135 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching regimen
Number of subjects: 2
Study 17391773 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine monotherapy
Number of subjects: 0
Study 17391773 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine combined with Li/DVP
Number of subjects: 0
Study 12213507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) treatment programme for 12 weeks
Number of subjects: 135
Study 10646745 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa with part-time occlusion (3 h/day) for 7 weeks
Number of subjects: 13
Study 10646745 — intervention group
Group type: COMPARATOR
Intervention: Levodopa-carbidopa without part-time occlusion
Number of subjects: 13
Study 10646745 — intervention group
Group type: COMPARATOR
Intervention: Comparison between occlusion and no occlusion groups
Number of subjects: 13
Study 10646745 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa with part-time occlusion
Number of subjects: 13
Study 7667054 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluids (65 to 70% of normal maintenance)
Number of subjects: 50
Study 7667054 — intervention group
Group type: COMPARATOR
Intervention: Normal maintenance fluids
Number of subjects: 50
Study 7667054 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluids
Number of subjects: 50
Study 2710502 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% carteolol hydrochloride
Number of subjects: 0
Study 2710502 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 0
Study 937076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide
Number of subjects: 53
Study 937076 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 53
Study 937076 — intervention group
Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 53
Study 30964970 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Philips Sonicare DiamondClean Smart with Premium Gum Care brush head) in Gum Health mode (DC-GH)
Number of subjects: 188
Study 30964970 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Philips Sonicare DiamondClean Smart with Premium Gum Care brush head) in Clean mode (DC-C)
Number of subjects: 188
Study 30964970 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (MTB)
Number of subjects: 188
Study 28157728 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC-15L
Number of subjects: 225
Study 28157728 — intervention group
Group type: COMPARATOR
Intervention: NASHA
Number of subjects: 225
Study 27009270 — intervention group
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Number of subjects: 0
Study 27009270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25010119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (small group activities to build coping skills)
Number of subjects: 256
Study 25010119 — intervention group
Group type: COMPARATOR
Intervention: Standard care condition
Number of subjects: 256
Study 22327702 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmable valves with gravitational units
Number of subjects: 250
Study 22327702 — intervention group
Group type: COMPARATOR
Intervention: Programmable valves without gravitational units
Number of subjects: 250
Study 20184287 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipine (150 mg, i.v., daily) for 14 days
Number of subjects: 136
Study 20184287 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin (400 ml, i.v., daily) for 14 days
Number of subjects: 136
Study 20184287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol (300 mg, i.v., daily) for 14 days
Number of subjects: 136
Study 17917897 — intervention group
Group type: EXPERIMENTAL
Intervention: Desk height
Number of subjects: 101
Study 17917897 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair height
Number of subjects: 101
Study 17917897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting posture analysis
Number of subjects: 101
Study 16142873 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneous injection twice weekly for 24 weeks
Number of subjects: 277
Study 16142873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 12100440 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 142
Study 12100440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine/pyrimethamine (SP)
Number of subjects: 142
Study 10440621 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose sparfloxacin (400 mg on day 1)
Number of subjects: 1175
Study 10440621 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day sparfloxacin (400 mg loading dose on day 1 followed by 200 mg once daily for 2 additional days)
Number of subjects: 1175
Study 10440621 — intervention group
Group type: COMPARATOR
Intervention: 7-day ciprofloxacin (250 mg twice daily for 7 days)
Number of subjects: 1175
Study 7849366 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior circulation (internal carotid arteries)
Number of subjects: 21
Study 7849366 — intervention group
Group type: COMPARATOR
Intervention: Posterior circulation (vertebral arteries)
Number of subjects: 21
Study 1495785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg 5 times daily) for 7 days
Number of subjects: 86
Study 1495785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg 5 times daily) for 14 days
Number of subjects: 86
Study 1495785 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (as a reference)
Number of subjects: 86
Study 6496206 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive condition (telephone contact by an assistant in the original smoking cessation treatment program)
Number of subjects: 0
Study 6496206 — intervention group
Group type: COMPARATOR
Intervention: Non-reactive condition (telephone contact by an employee of a market research firm)
Number of subjects: 0
Study 30320665 — intervention group
Group type: EXPERIMENTAL
Intervention: Donkey milk-derived fortifier (DF)
Number of subjects: 156
Study 30320665 — intervention group
Group type: COMPARATOR
Intervention: Bovine milk-derived fortifier (BF)
Number of subjects: 156
Study 30571192 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) measurement
Number of subjects: 1767
Study 30571192 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of hs-cTnI
Number of subjects: 1767
Study 30571192 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone treatment
Number of subjects: 1767
Study 27084538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral elemental diet (ED) - 300 kcal of ED plus regular diet for 6-8 weeks after surgery
Number of subjects: 112
Study 27084538 — intervention group
Group type: COMPARATOR
Intervention: Control diet - regular diet alone
Number of subjects: 112
Study 27084538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral elemental diet (ED) - in total gastrectomy patients
Number of subjects: 112
Study 27084538 — intervention group
Group type: COMPARATOR
Intervention: Control diet - in total gastrectomy patients
Number of subjects: 112
Study 28381222 — intervention group
Group type: EXPERIMENTAL
Intervention: Zarit Burden Interview (ZBI)
Number of subjects: 223
Study 28381222 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement Evaluation Questionnaire (IEQ)
Number of subjects: 223
Study 28381222 — intervention group
Group type: COMPARATOR
Intervention: ZBI and IEQ
Number of subjects: 223
Study 23710734 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon alfa-2b/ribavirin (triple therapy)
Number of subjects: 0
Study 23710734 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir (t.d.s. dosing interval 7-9 h)
Number of subjects: 0
Study 21777259 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 572
Study 21777259 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list for BMI)
Number of subjects: 572
Study 19911678 — intervention group
Group type: EXPERIMENTAL
Intervention: C/BPO HE
Number of subjects: 382
Study 19911678 — intervention group
Group type: COMPARATOR
Intervention: A/BPO
Number of subjects: 382
Study 17151593 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat products with increasing beta-glucan content
Number of subjects: 10
Study 17151593 — intervention group
Group type: COMPARATOR
Intervention: Reference glucose load
Number of subjects: 10
Study 15540913 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-flow (CF) shunt
Number of subjects: 103
Study 15540913 — intervention group
Group type: COMPARATOR
Intervention: Conventional shunt (control group)
Number of subjects: 103
Study 11176087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine
Number of subjects: 100
Study 9573502 — intervention group
Group type: EXPERIMENTAL
Intervention: hBNP 0.025 or 0.05 microgram/kg/min
Number of subjects: 16
Study 9573502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7796899 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use
Number of subjects: 4023
Study 7796899 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm use
Number of subjects: 4023
Study 7796899 — intervention group
Group type: EXPERIMENTAL
Intervention: The pill
Number of subjects: 4023
Study 7796899 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD
Number of subjects: 4023
Study 7796899 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasectomy
Number of subjects: 4023
Study 7796899 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sterilization
Number of subjects: 4023
Study 2084879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (40 or 60 mg)
Number of subjects: 12
Study 2084879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 or 30 mg)
Number of subjects: 12
Study 2084879 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine
Number of subjects: 12
Study 395626 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 29
Study 395626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30660018 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (1 drop, 4 times a day for 3 days)
Number of subjects: 20
Study 30660018 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (1 drop, 4 times a day for 3 days)
Number of subjects: 20
Study 28323237 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Macintosh laryngoscopy (DL)
Number of subjects: 132
Study 28323237 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath® MAC video laryngoscope (MM)
Number of subjects: 132
Study 25361222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (0.5 μg/kg/h) for 5 days
Number of subjects: 40
Study 25361222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pure saline for 5 days)
Number of subjects: 40
Study 23306726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C augmented trabeculectomy
Number of subjects: 165
Study 21161666 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CHOc)
Number of subjects: 12
Study 21161666 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CHO)
Number of subjects: 12
Study 21161666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 21161666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAc)
Number of subjects: 12
Study 19241334 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowatinex, 100 mg, 3 times per day
Number of subjects: 100
Study 19241334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17560414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical and minimal access strategies
Number of subjects: 0
Study 17560414 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 15291124 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg tid for 4 days
Number of subjects: 30
Study 15291124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11304896 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg dose of atrasentan
Number of subjects: 24
Study 11304896 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dose of atrasentan
Number of subjects: 24
Study 11304896 — intervention group
Group type: EXPERIMENTAL
Intervention: 23.25 mg dose of atrasentan
Number of subjects: 24
Study 11304896 — intervention group
Group type: EXPERIMENTAL
Intervention: 139.5 mg dose of atrasentan
Number of subjects: 24
Study 11304896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11304896 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of atrasentan
Number of subjects: 24
Study 9385283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (200 IU daily for 28 days)
Number of subjects: 100
Study 9385283 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 100
Study 9113120 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (Navoban) monotherapy
Number of subjects: 87
Study 9113120 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron plus dexamethasone
Number of subjects: 87
Study 9113120 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron plus metoclopramide
Number of subjects: 87
Study 9113120 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron and tropisetron plus metoclopramide
Number of subjects: 87
Study 9113120 — intervention group
Group type: EXPERIMENTAL
Intervention: All antiemetic treatments
Number of subjects: 87
Study 2140659 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (THA) with succinylcholine
Number of subjects: 20
Study 2140659 — intervention group
Group type: COMPARATOR
Intervention: Alcuronium
Number of subjects: 20
Study 347574 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (subcutaneous doses)
Number of subjects: 18
Study 347574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31918760 — intervention group
Group type: COMPARATOR
Intervention: Transdiagnostic treatment protocol using an adapted version of the Problem Management Plus (PM+) protocol, consisting of six 90-min sessions.
Number of subjects: 120
Study 30753642 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal tenofovir (TFV) 1% gel
Number of subjects: 566
Study 30753642 — intervention group
Group type: COMPARATOR
Intervention: No TFV detected in plasma
Number of subjects: 566
Study 30753642 — intervention group
Group type: EXPERIMENTAL
Intervention: TFV detection in plasma
Number of subjects: 566
Study 30753642 — intervention group
Group type: EXPERIMENTAL
Intervention: TFV detection in plasma (adjusted)
Number of subjects: 566
Study 28271493 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbis' microsphere prednisone formulation
Number of subjects: 24
Study 28271493 — intervention group
Group type: COMPARATOR
Intervention: Control formulation
Number of subjects: 24
Study 28271493 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Roxanne Laboratories)
Number of subjects: 24
Study 26095784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg) every 2 weeks
Number of subjects: 565